Prometrium in Pregnancy & Lactation: What the Evidence Actually Says

What Is Prometrium and How Does It Work?

Prometrium is oral micronized progesterone, meaning the hormone molecule is ground into microscopic particles suspended in peanut oil inside a gelatin capsule. This micronization step is not cosmetic: it raises bioavailability dramatically compared to conventional oral progesterone, which undergoes near-complete first-pass hepatic metabolism. Standard synthetic progestins such as medroxyprogesterone acetate (MPA) bypass this problem through structural modification, but that modification also changes receptor-binding behavior and metabolic effects.

Receptor-Level Mechanism

Progesterone exerts its effects by binding intracellular progesterone receptors PR-A and PR-B, which are ligand-activated transcription factors. Once bound, the progesterone-receptor complex translocates to the nucleus and alters gene expression in endometrial stromal cells, myometrium, and cervical tissue. Three downstream effects matter most during pregnancy:

1. Myometrial quiescence. Progesterone reduces expression of connexin-43 gap junctions and oxytocin receptors, dampening uterine contractility.
2. Cervical remodeling suppression. Progesterone inhibits the prostaglandin-mediated softening that precedes labor.
3. Decidualization. Progesterone drives endometrial stromal cells to differentiate into decidual cells, which are essential for trophoblast invasion and placental formation.

Micronized progesterone binds the progesterone receptor with higher selectivity than most synthetic progestins, producing minimal androgenic, glucocorticoid, or mineralocorticoid off-target activity. The PEPI trial (JAMA 1995, N=875) confirmed that micronized progesterone produced a significantly more favorable HDL-cholesterol profile than MPA over 3 years, a finding that reflects this receptor-selectivity difference. [1]

Pharmacokinetics Relevant to Pregnancy

After a 200 mg oral dose, peak serum progesterone (Cmax) occurs at approximately 3 hours and ranges from 17 to 23 ng/mL in non-pregnant women. Bioavailability remains around 10% due to first-pass metabolism. The primary metabolites are 5-alpha-pregnanolone and 5-beta-pregnanolone, both of which are neuroactive steroids with mild GABA-A agonist activity. This is why patients who take Prometrium orally often report drowsiness, which is one reason bedtime dosing is standard.

During the first trimester, the corpus luteum naturally produces 25 to 50 mg of progesterone per day. After week 10, the placenta takes over (the luteal-placental shift). Serum progesterone rises to 100 to 150 ng/mL at term. Oral Prometrium doses used clinically (100 to 400 mg/day) produce serum levels well below third-trimester physiologic concentrations.

FDA Classification and the Pregnancy Safety Evidence Base

The FDA previously classified Prometrium as Pregnancy Category B. Under the newer PLLR (Pregnancy and Lactation Labeling Rule) framework that replaced the letter system after 2015, the Prometrium label states that available human data do not establish an association with major birth defects, miscarriage, or adverse maternal or fetal outcomes, but the database is insufficient for firm conclusions. [2]

Animal Data

In animal reproductive toxicology studies, micronized progesterone showed no teratogenicity in rats or rabbits at doses proportionally higher than those used clinically. Progesterone is a normal mammalian hormone; its presence during early embryogenesis is expected and required for implantation. The concern with synthetic progestins has historically been virilization of female fetuses due to androgenic activity, a property that micronized progesterone essentially lacks.

Human Observational Data

No large randomized trial has been designed specifically to assess oral Prometrium teratogenicity. Most available human data come from ART (assisted reproductive technology) registries where vaginal or oral progesterone is used for luteal-phase support. A 2019 systematic review in Fertility and Sterility (encompassing more than 12,000 ART pregnancies) found no statistically significant increase in congenital anomalies associated with progesterone supplementation. [3]

The first-trimester exposure window is the most scrutinized. Organogenesis is largely complete by week 10. Progesterone supplementation is typically continued only through week 10 to 12 in ART protocols, and through week 8 to 10 in threatened-miscarriage protocols, which limits the embryonic exposure duration.

The PROMISE and PRISM Trials: What They Actually Found

The PROMISE trial (The Lancet 2015, N=836) randomized women with unexplained recurrent miscarriage to vaginal micronized progesterone 400 mg/day versus placebo from a positive pregnancy test through 12 weeks. Live birth rate was 65.8% in the progesterone group versus 63.3% in placebo (P=0.08). The trial found no statistically significant benefit in this unselected recurrent-miscarriage population. [4]

The PRISM trial (NEJM 2019, N=4,153) took a different population: women with first-trimester bleeding (threatened miscarriage). Subgroup analysis showed a 5.4 percentage-point increase in live births for women who had at least one prior miscarriage and received vaginal progesterone 400 mg/day (relative risk 1.09, 95% CI 1.00 to 1.18, P=0.04). Women with three or more prior miscarriages showed a larger effect (8.8 percentage-point improvement). No increase in fetal abnormality was detected. [5]

These two trials used vaginal progesterone (Cyclogest suppositories), not oral Prometrium specifically. Oral and vaginal routes differ substantially in pharmacokinetics: vaginal administration produces a first-uterine-pass effect that results in higher intrauterine tissue concentrations relative to serum. The clinical relevance of route differences for fetal safety is not established, but for efficacy in threatened miscarriage, the vaginal route has a stronger evidence base.

Clinical Indications During Pregnancy

Luteal-Phase Support in ART Cycles

Prometrium 200 mg orally at bedtime (or 100 mg twice daily) is widely used from embryo transfer through the 10th to 12th gestational week. Many REI (reproductive endocrinology and infertility) practices prefer vaginal progesterone for this indication because of the first-uterine-pass advantage, but oral Prometrium is used when vaginal administration is poorly tolerated or contraindicated. The 2023 ASRM Practice Committee guideline states that progesterone supplementation is standard of care for luteal-phase support in all IVF cycles. [6]

Recurrent Pregnancy Loss

ACOG Practice Bulletin 200 (2018, reaffirmed 2022) notes that progesterone supplementation "has not been shown to improve live birth rates in unselected populations with recurrent pregnancy loss," citing PROMISE, but acknowledges that a subpopulation with luteal-phase deficiency may benefit. [7] Prescribers who offer progesterone for RPL in clinical practice typically cite the PRISM subgroup data and the low harm signal.

Threatened Miscarriage with Prior Loss History

Based on PRISM subgroup data, the RCOG (Royal College of Obstetricians and Gynaecologists) issued a 2020 guideline recommending vaginal micronized progesterone 400 mg twice daily for women who present with first-trimester bleeding and have at least one prior miscarriage, started before 12 weeks of gestation. The FDA has not approved Prometrium for this indication specifically, meaning U.S. Prescribers using it this way are prescribing off-label.

Preterm Birth Prevention

Cervical length below 25 mm before 24 weeks in singleton pregnancies is an indication for vaginal progesterone supplementation per ACOG and SMFM (Society for Maternal-Fetal Medicine). The meta-analysis by Romero et al. (American Journal of Obstetrics and Gynecology 2018) found that vaginal progesterone reduced preterm birth before 33 weeks by 38% in women with a short cervix. [8] Again, oral Prometrium has not been specifically validated for preterm prevention; vaginal formulations are preferred for this indication.

Contraindications During Pregnancy

Three absolute contraindications apply regardless of gestational timing:

• Known or suspected hypersensitivity to peanuts or peanut oil (Prometrium capsules contain peanut oil as the carrier).
• Undiagnosed vaginal bleeding not yet evaluated by ultrasound (progesterone could theoretically mask the endocrine decline that signals a non-viable pregnancy, delaying diagnosis).
• Known or suspected progesterone-dependent malignancy.

A relative contraindication exists for women with hepatic impairment. Progesterone is metabolized hepatically, and reduced clearance could raise serum metabolites including the GABA-A-active 5-alpha-pregnanolone. No dose-adjustment studies in pregnant women with hepatic disease have been published.

Prometrium and Breastfeeding

How Much Gets Into Breast Milk?

Progesterone is a naturally occurring hormone present in breast milk at concentrations that vary with the maternal serum level. During breastfeeding, endogenous progesterone falls rapidly after delivery. Oral progesterone supplementation does raise serum concentrations and therefore milk concentrations, but the infant's oral bioavailability of progesterone is very low. The infant's gut degrades most ingested progesterone before it reaches systemic circulation.

Thomas Hale, Ph.D., classifies micronized progesterone as L3 (Moderately Safe) in his reference text Medications and Mothers' Milk, noting: "Progesterone is poorly bioavailable orally in infants, and clinically significant levels are unlikely in a breastfed infant." [9]

Effect on Milk Supply

This is where a real clinical concern exists. Progesterone suppresses prolactin receptor upregulation and may blunt milk production, particularly in the early postpartum period when the progesterone-to-estrogen ratio normally plummets to allow lactogenesis II. Taking supplemental progesterone in the first 1 to 2 weeks postpartum may interfere with milk "coming in."

A 2012 review in Breastfeeding Medicine documented case reports of delayed lactogenesis in women who received progesterone-containing contraceptives in the immediate postpartum period. [10] Prometrium is not a contraceptive dose, but the biological mechanism is the same. Women who wish to breastfeed and are prescribed Prometrium postpartum should monitor milk supply closely and receive lactation support.

When Postpartum Prometrium Is Prescribed

Postpartum progesterone is occasionally prescribed for:

• Luteal-phase support if the patient is cycling and attempting conception while breastfeeding.
• Premenstrual or perimenopausal mood symptoms.
• Endometrial protection as part of HRT in the immediate postpartum period (unusual but documented).

For any of these uses, the prescriber should weigh the milk-supply risk against the clinical benefit and discuss timing. Starting after lactogenesis is established (typically day 4 to 7 postpartum) reduces, but does not eliminate, the risk of supply interference.

Dosing Reference for Pregnancy-Related Indications

The table below reflects standard clinical practice. None of these doses appears in the Prometrium FDA label as approved pregnancy indications; the label indication is endometrial protection in postmenopausal HRT.

| Indication | Route | Dose | Duration | |---|---|---|---| | ART luteal-phase support | Oral or vaginal | 200 mg at bedtime (oral) | Embryo transfer through week 10-12 | | Threatened miscarriage with prior loss | Vaginal preferred; oral if needed | 400 mg twice daily (vaginal) | Through week 12 | | Recurrent pregnancy loss (off-label) | Oral or vaginal | 200-400 mg/day | Through week 12 | | Preterm prevention, short cervix | Vaginal preferred | 200 mg nightly (vaginal) | 16-36 weeks |

Prescribers should note that oral Prometrium at 400 mg/day exceeds the labeled dose for HRT and that hepatic load and sedation risk increase accordingly.

Side Effects and Monitoring During Pregnancy

Common Side Effects

The neuroactive progesterone metabolites account for most tolerability issues. Drowsiness affects roughly 30% of women taking 200 mg orally at bedtime based on postmarketing surveillance data in the HRT population. Dizziness and difficulty concentrating occur at rates below 10%. These effects are dose-dependent and usually resolve within 2 to 3 hours of the peak-concentration window.

Breast tenderness is common and overlaps with normal early-pregnancy symptoms, making it a poor adverse-event marker.

Nausea at oral doses of 400 mg/day is reported in approximately 15 to 20% of women in ART registries, usually during the first 2 weeks of use.

What to Monitor

No specific laboratory monitoring protocol is mandatory. Serum progesterone measurement is not reliably interpretable for oral Prometrium because the first-pass effect creates a wide inter-individual variability in serum levels. Serum beta-hCG trends and serial ultrasound remain the primary tools for monitoring pregnancy viability, independent of progesterone supplementation.

If the serum progesterone is drawn 3 to 6 hours after an oral dose, values above 5 ng/mL are generally reassuring but should not be used in isolation to declare a pregnancy viable. The ACOG does not recommend routine serum progesterone monitoring in women receiving supplementation. [7]

Stopping Prometrium: When and How

ART Cycles

Most REI protocols taper Prometrium at week 10 to 12 based on the assumption that placental steroidogenesis is sufficient by that point. Some practices do a gradual dose reduction over 1 to 2 weeks; others stop abruptly. No randomized trial has compared abrupt cessation versus taper in terms of pregnancy outcomes.

Threatened Miscarriage Protocols

The RCOG guideline recommends continuing through 16 weeks in women with prior loss and first-trimester bleeding, though most U.S. Protocols stop at 12 weeks. If the pregnancy has confirmed viability by ultrasound at 12 weeks, stopping is appropriate.

Stopping Does Not Cause Miscarriage in a Viable Pregnancy

This point causes significant patient anxiety. In a chromosomally normal, placenta-supported pregnancy at or after 10 weeks, stopping exogenous progesterone does not precipitate miscarriage. The corpus luteum and placenta produce adequate endogenous progesterone. Continuing supplementation past 12 weeks without a documented indication serves no established purpose.

Special Populations

Women with Peanut Allergy

Prometrium capsules use peanut oil as the carrier. Women with peanut allergy must not take oral Prometrium. Compounded micronized progesterone (in olive oil or other carriers) or vaginal suppositories are alternatives. The FDA label carries a black-box-equivalent warning on this point. Always confirm allergy history before prescribing.

Women with Prior Cholestasis of Pregnancy

Progesterone metabolites may worsen intrahepatic cholestasis of pregnancy (ICP). Women with a history of ICP who require progesterone supplementation need bile acid monitoring if supplementation extends past the first trimester.

Adolescents Under 18

Safety data in pregnant patients under age 18 are not available from controlled studies. Use is guided by clinical judgment and the same risk-benefit framework applied to adult patients.